Carin P de Villiers1, Lize van der Merwe1, Lia Crotti1, Althea Goosen1, Alfred L George1, Peter J Schwartz1, Paul A Brink1, Johanna C Moolman-Smook1, Valerie A Corfield1. 1. From the Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Medical Research Council (MRC) Centre for Molecular and Cellular Biology, (C.P.d.V., L.v.d.M., J.C.M.-S., V.A.C.), and Department of Internal Medicine (A.G., P.A.B.), Stellenbosch University, Stellenbosch, South Africa; Department of Statistics, University of Western Cape, Bellville, South Africa (L.v.d.M.); IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy (L.C., P.J.S.); Department of Molecular Medicine, University of Pavia, Pavia, Italy (L.C.); Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany (L.C.); and Departments of Medicine and Pharmacology, and Institute for Integrative Genomics, Vanderbilt University, Nashville, TN (A.L.G.).
Abstract
BACKGROUND: Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, often results in devastating outcomes, including sudden cardiac death. Variable expression, independently from the primary disease-causing mutation, can partly be explained by genetic modifiers. This study investigates variants in a known LQTS-causative gene, AKAP9, for potential LQTS-type 1-modifying effects. METHODS AND RESULTS: Members of a South African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the identical-by-descent KCNQ1 p.Ala341Val (A341V) mutation were evaluated for modifying effects of AKAP9 variants on heart rate-corrected QT interval (QTc), cardiac events, and disease severity. Tag single nucleotide polymorphisms in AKAP9 rs11772585, rs7808587, rs2282972, and rs2961024 (order, 5'-3'positive strand) were genotyped. Associations between phenotypic traits and alleles, genotypes, and haplotypes were statistically assessed, adjusting for the degree of relatedness and confounding variables. The rs2961024 GG genotype, always represented by CGCG haplotype homozygotes, revealed an age-dependent heart rate-corrected QT interval increase (1% per additional 10 years) irrespective of A341V mutation status (P=0.006). The rs11772585 T allele, found uniquely in the TACT haplotype, more than doubled (218%) the risk of cardiac events (P=0.002) in the presence of A341V; additionally, it increased disease severity (P=0.025). The rs7808587 GG genotype was associated with a 74% increase in cardiac event risk (P=0.046), whereas the rs2282972 T allele, predominantly represented by the CATT haplotype, decreased risk by 53% (P=0.001). CONCLUSIONS: AKAP9 has been identified as an LQTS-type 1-modifying gene. Variants investigated altered heart rate-corrected QT interval irrespective of mutation status, as well as cardiac event risk, and disease severity, in mutation carriers.
BACKGROUND: Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, often results in devastating outcomes, including sudden cardiac death. Variable expression, independently from the primary disease-causing mutation, can partly be explained by genetic modifiers. This study investigates variants in a known LQTS-causative gene, AKAP9, for potential LQTS-type 1-modifying effects. METHODS AND RESULTS: Members of a South African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the identical-by-descent KCNQ1 p.Ala341Val (A341V) mutation were evaluated for modifying effects of AKAP9 variants on heart rate-corrected QT interval (QTc), cardiac events, and disease severity. Tag single nucleotide polymorphisms in AKAP9 rs11772585, rs7808587, rs2282972, and rs2961024 (order, 5'-3'positive strand) were genotyped. Associations between phenotypic traits and alleles, genotypes, and haplotypes were statistically assessed, adjusting for the degree of relatedness and confounding variables. The rs2961024 GG genotype, always represented by CGCG haplotype homozygotes, revealed an age-dependent heart rate-corrected QT interval increase (1% per additional 10 years) irrespective of A341V mutation status (P=0.006). The rs11772585 T allele, found uniquely in the TACT haplotype, more than doubled (218%) the risk of cardiac events (P=0.002) in the presence of A341V; additionally, it increased disease severity (P=0.025). The rs7808587 GG genotype was associated with a 74% increase in cardiac event risk (P=0.046), whereas the rs2282972 T allele, predominantly represented by the CATT haplotype, decreased risk by 53% (P=0.001). CONCLUSIONS: AKAP9 has been identified as an LQTS-type 1-modifying gene. Variants investigated altered heart rate-corrected QT interval irrespective of mutation status, as well as cardiac event risk, and disease severity, in mutation carriers.
Authors: Ilan Goldenberg; Samuel Horr; Arthur J Moss; Coeli M Lopes; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Mark L Andrews; Jennifer L Robinson; Emanuela H Locati; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Carlo Napolitano; Pyotr G Platonov; Silvia G Priori; Ming Qi; Peter J Schwartz; Wataru Shimizu; Jeffrey A Towbin; G Michael Vincent; Arthur A M Wilde; Li Zhang Journal: J Am Coll Cardiol Date: 2011-01-04 Impact factor: 24.094
Authors: Dan E Arking; Arne Pfeufer; Wendy Post; W H Linda Kao; Christopher Newton-Cheh; Morna Ikeda; Kristen West; Carl Kashuk; Mahmut Akyol; Siegfried Perz; Shapour Jalilzadeh; Thomas Illig; Christian Gieger; Chao-Yu Guo; Martin G Larson; H Erich Wichmann; Eduardo Marbán; Christopher J O'Donnell; Joel N Hirschhorn; Stefan Kääb; Peter M Spooner; Thomas Meitinger; Aravinda Chakravarti Journal: Nat Genet Date: 2006-04-30 Impact factor: 38.330
Authors: P J Schwartz; S G Priori; C Spazzolini; A J Moss; G M Vincent; C Napolitano; I Denjoy; P Guicheney; G Breithardt; M T Keating; J A Towbin; A H Beggs; P Brink; A A Wilde; L Toivonen; W Zareba; J L Robinson; K W Timothy; V Corfield; D Wattanasirichaigoon; C Corbett; W Haverkamp; E Schulze-Bahr; M H Lehmann; K Schwartz; P Coumel; R Bloise Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: Paula L Hedley; Poul Jørgensen; Sarah Schlamowitz; Romilda Wangari; Johanna Moolman-Smook; Paul A Brink; Jørgen K Kanters; Valerie A Corfield; Michael Christiansen Journal: Hum Mutat Date: 2009-11 Impact factor: 4.878
Authors: Lei Chen; Michelle L Marquardt; David J Tester; Kevin J Sampson; Michael J Ackerman; Robert S Kass Journal: Proc Natl Acad Sci U S A Date: 2007-12-19 Impact factor: 11.205
Authors: Alberto Porta; Giulia Girardengo; Vlasta Bari; Alfred L George; Paul A Brink; Althea Goosen; Lia Crotti; Peter J Schwartz Journal: J Am Coll Cardiol Date: 2015-02-03 Impact factor: 24.094
Authors: Peter J Schwartz; Michael J Ackerman; Charles Antzelevitch; Connie R Bezzina; Martin Borggrefe; Bettina F Cuneo; Arthur A M Wilde Journal: Nat Rev Dis Primers Date: 2020-07-16 Impact factor: 52.329
Authors: Peter J Schwartz; Cristina Moreno; Maria-Christina Kotta; Matteo Pedrazzini; Lia Crotti; Federica Dagradi; Silvia Castelletti; Kristina H Haugaa; Isabelle Denjoy; Maria A Shkolnikova; Paul A Brink; Marshall J Heradien; Sandrine R M Seyen; Roel L H M G Spätjens; Carla Spazzolini; Paul G A Volders Journal: Eur Heart J Date: 2021-12-07 Impact factor: 29.983
Authors: Justyna Karolczak; Magdalena Sobczak; Krzysztof Skowronek; Maria Jolanta Rędowicz Journal: Biomed Res Int Date: 2015-04-16 Impact factor: 3.411